1:00

10

Asgharzadeh

Gene Expression Signatures Identify Prognostic Subgroups of Metastatic Neuroblastomas Lacking [italic]MYCN[/italic] Amplification

1:15

11

Lastowska

Identification of Primary Expression Signatures Associated with Genomic Alterations in Neuroblastomas

1:30

12

Nakagawara

Combined Genomic and Molecular Signatures Stratify the New Therapeutic Risk Groups of Neuroblastoma

1:45

13

Schramm

Combining Use of Oligonucleotide Microarrays and Microfluidic Cards: A Novel Strategy for Candidate Gene Analysis in Neuroblastoma

2:00

14

Van Roy

High Resolution Mapping of 17q Breakpoints and Assessment of Gene Expression Status of 17q Genes in a Proposed Critical Region at 17q21.32 in Neuroblastoma

2:15

15

Warnat

Meta-Analysis of Gene Expression Data for Non-Amplified Advanced Stage Neuroblastoma Tumors

2:30

16

Ohira

Practical Application and Validation of a Microarray-Based Diagnostic System for Aiming at the New Risk Classification of Neuroblastoma

2:45

17

De Preter

Transcriptome Profiles of Human Foetal Adrenal Neuroblasts: Resources for the Study of Early Sympathetic Nervous System Development and Neuroblastoma Oncogenesis

3:00

18

Oppenheimer

Transcriptional Programs Associated with Retinoic Acid Induced Differentiation in Neuroblastoma Detected by Gene Expression Array

3:15

19

Schulte

Micro-RNA Expression Analysis in Neuroblastoma Using Oligonucleotide Arrays

3:30

20

Avigad

Micro-RNA Deletion in Neuroblastoma: A Possible Alternative Mechanism of MYCN Overexpression

3:45

21

Grandinetti

MicroRNA Expression Analysis in Human Neuroblastoma Cell Line Variants

4:00

Break